Join to view full profile
161 Fort Washington AveNew York, NY 10032
Phone+1 646-317-6041
Fax+1 212-305-6861
Dr. Ingham is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
NYU Grossman School of MedicineResidency, Internal Medicine, 2010 - 2013
University of Massachusetts Medical SchoolClass of 2010
Certifications & Licensure
NY State Medical License 2013 - 2028
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 18 citationsPhase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.Kevin J Harrington, Stephane Champiat, Joshua D Brody, Byoung Chul Cho, Emanuela Romano
Clinical Cancer Research. 2025-08-14 - 4 citationsSingle-Cell Profiling of Sarcomas from Archival Tissue Reveals Programs Associated with Resistance to Immune Checkpoint Blockade.Karan Luthria, Parin Shah, Blake Caldwell, Johannes C Melms, Sinan Abuzaid
Clinical Cancer Research. 2024-10-01 - 3 citationsPhase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma.Brian A Van Tine, Matthew A Ingham, Steven Attia, Christian F Meyer, John D Baird
Journal of Clinical Oncology. 2024-07-10
Press Mentions
Intensity Therapeutics' Data on Lead Asset, INT230-6, Accepted for Three Presentations at Key Upcoming Clinical Oncology Conferences in NovemberNovember 1st, 2022- Intensity Therapeutics Reports Promising Overall Survival Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab or Ipilimumab to Treat Solid Tumors, at the Society for Immunotherapy of Cancer's (SITC) 36th Annual MeetingNovember 13th, 2021
- Intensity Therapeutics’ INT230-6 Demonstrates Efficacy as Either Monotherapy or in Combination with Checkpoint Inhibitors in Patients with Relapsed, Refractory, Metastatic Solid TumorsJune 2nd, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
